Misplaced Pages

Bremelanotide: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 15:26, 22 November 2006 editTom harrison (talk | contribs)Administrators47,534 editsm moved PT-141 to Bremelanotide: merging page histories← Previous edit Revision as of 15:31, 22 November 2006 edit undoTom harrison (talk | contribs)Administrators47,534 edits merging page historiesNext edit →
Line 1: Line 1:
]
⚫ #REDIRECT ]

'''Bremelanotide''' (formerly PT-141) is the generic term for a new ] for use in treating ] in men (] or ]) as well as sexual dysfunction in women (]). It is a ] ]. Unlike ] and other related medications, it does not act upon the vascular system, but directly increases sexual desire. Bremelanotide is a spray introduced nasally.

Originally, the ] ] that bremelanotide was developed from was tested as a sunless tanning agent. In initial testing, Melanotan II did induce tanning but additionally caused sexual arousal and spontaneous erections as unexpected side effects in eight out of the ten original male volunteer test subjects. In clinical studies, bremelanotide has been shown to be effective in treating male sexual and erectile dysfunction as well as female sexual dysfunction. It is currently being tested by ].

Bremelanotide is a cyclic hepta-] ] analog of ] (alpha-MSH) that activates the ]s ] and ] in the ]. It has the ] Ac-Nle-''cyclo''-OH or ''cyclo''-alpha-MSH-(4-10). PT-141 is a ] of ] that lacks the ] ] ]. Its molecular forumla is C<sub>50</sub>H<sub>68</sub>N<sub>14</sub>O<sub>10</sub> with a molecular weight of 1025.2.

In the ] it is currently in a ] ].

== External links ==
* The company that has developed bremelanotide.
* bremelanotide (PT-141) patent (Appl. No.:040547)
* bremelanotide (PT-141) patent (Appl. No.:066501)
*
* A scientific study with female rats.
* (in German).
* The June 2006 release of summarized Phase IIa test results for women, which indicated significantly increased sexual desire and arousal (67% and 72% respectively) in women diagnosed with ].
* Norman Levine, MD; researcherss on Melanotan at University of Arizona Dermatology
* (]; cached HTML version is )

]
]
]
]
]
<!-- The wikilinks below are interlanguage links. -->
⚫ ]

Revision as of 15:31, 22 November 2006

Chemical structure of Bremelanotide (formerly PT-141) CAS# 189691-06-3

Bremelanotide (formerly PT-141) is the generic term for a new medication for use in treating sexual dysfunction in men (erectile dysfunction or impotence) as well as sexual dysfunction in women (sexual arousal disorder). It is a synthetic aphrodisiac. Unlike Viagra and other related medications, it does not act upon the vascular system, but directly increases sexual desire. Bremelanotide is a spray introduced nasally.

Originally, the peptide Melanotan II that bremelanotide was developed from was tested as a sunless tanning agent. In initial testing, Melanotan II did induce tanning but additionally caused sexual arousal and spontaneous erections as unexpected side effects in eight out of the ten original male volunteer test subjects. In clinical studies, bremelanotide has been shown to be effective in treating male sexual and erectile dysfunction as well as female sexual dysfunction. It is currently being tested by Palatin Technologies.

Bremelanotide is a cyclic hepta-peptide lactam analog of alpha-melanocyte-stimulating hormone (alpha-MSH) that activates the melanocortin receptors MC3-R and MC4-R in the central nervous system. It has the amino acid sequence Ac-Nle-cyclo-OH or cyclo-alpha-MSH-(4-10). PT-141 is a metabolite of Melanotan II that lacks the C-terminal amide function. Its molecular forumla is C50H68N14O10 with a molecular weight of 1025.2.

In the United States it is currently in a Phase III clinical trial.

External links

Categories: